Fosfomycin
Based on 15 publication(s) in Google Scholar
Fosfomycin (MK-0955) is a broad-spectrum antibiotic. Fosfomycin can cross blood-brain barrier penetrating, and irreversibly inhibits an early stage in cell wall synthesis. Fosfomycin shows anti-bacteria activity for a range of bacteria, including multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) bacteria.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 23155-02-4
- Formel: C3H7O4P
- Molecular Weight:138.06
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Fosfomycin
More- Nat Commun. 2022 Mar 2;13(1):1116. [Abstract]
- MedComm (2020). 2025 Jan 8;6(1):e70046. [Abstract]
- J Exp Med. 2026 Mar 2;223(3):e20241287. [Abstract]
- Antibiotics (Basel). 2021 Sep 14;10(9):1110. [Abstract]
- Front Cell Infect Microbiol. 2019 Jul 15:9:253. [Abstract]
- Molecules. 2025 Mar 9;30(6):1224. [Abstract]
- ACS Infect Dis. 2024 Aug 9;10(8):2961-2977. [Abstract]
- Microbiol Spectr. 2025 Sep 2;13(9):e0152125. [Abstract]
- Microb Pathog. 2026 Jan:210:108138. [Abstract]
- Infect Genet Evol. 2025 Sep:133:105780. [Abstract]
- J Antibiot (Tokyo). 2025 Mar;78(4):265-273. [Abstract]
- J Med Microbiol. 2019 Mar;68(3):493-502. [Abstract]
- Indian J Med Microbiol. 2026 May 14:62:101146. [Abstract]
- bioRxiv. 2025 January 19.
- bioRxiv. 2024 May 10.
Alle Antibiotic Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A-431 | IC50 |
≥100 μM
Compound: Fosfomycin
|
Cytotoxicity against human A431 cells after 72 hrs by crystal violet staining method
Cytotoxicity against human A431 cells after 72 hrs by crystal violet staining method
|
[PMID: 23266177] |
| Calu-6 | IC50 |
≥100 μM
Compound: Fosfomycin
|
Cytotoxicity against human Calu6 cells after 72 hrs by crystal violet staining method
Cytotoxicity against human Calu6 cells after 72 hrs by crystal violet staining method
|
[PMID: 23266177] |
| CAPAN-1 | IC50 |
≥100 μM
Compound: Fosfomycin
|
Cytotoxicity against human Capan1 cells after 72 hrs by crystal violet staining method
Cytotoxicity against human Capan1 cells after 72 hrs by crystal violet staining method
|
[PMID: 23266177] |
| Ca-Ski | IC50 |
≥100 μM
Compound: Fosfomycin
|
Cytotoxicity against human CaSki cells after 72 hrs by crystal violet staining method
Cytotoxicity against human CaSki cells after 72 hrs by crystal violet staining method
|
[PMID: 23266177] |
| HaCaT | IC50 |
≥100 μM
Compound: Fosfomycin
|
Cytotoxicity against human HaCaT cells after 72 hrs by crystal violet staining method
Cytotoxicity against human HaCaT cells after 72 hrs by crystal violet staining method
|
[PMID: 23266177] |
| MeWo | IC50 |
≥100 μM
Compound: Fosfomycin
|
Cytotoxicity against human MeWo cells after 72 hrs by crystal violet staining method
Cytotoxicity against human MeWo cells after 72 hrs by crystal violet staining method
|
[PMID: 23266177] |
Pharmacokinetic of Fosfomycin in Rats[4]
| Dibekacin Dose (mg) | Vdss (l/kg) | β (min-1) | T1/2 (min) | Urinary recovery (%) |
| 30 | 0.261 | 0.0244 | 28.4 | 85 |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Fischer 344 rats[3]
-
Dosage:320 mg/kg
-
Administration:Intramuscular injection, 5 schedules: 1 h, 0.5 h earlier than dibekacin, concomitantly, 0.5 h later and 1 h later; 11 days
-
Result:Reduced polyuria, proteinuria, enzymes and cytosine caused by dibecacin (40 mg/kg), followed by the previous treatment.
-
Animal Model:Dehydrated Wistar rat with acute renal failure (8-week-old)[4]
-
Dosage:120 mg/kg
-
Administration:Intravenous injection; once
-
Result:Recovered the exclusion rate of rats basically to normal, and improved the nephrotoxicity parameters.
Protects proximal tubular lysosomes from aminoglycosides by inhibiting myeloid formation and protecting the integrity of lysosomal membrane of rats treated with double bekacin.
Chemical Information
-
CAS. Nr. 23155-02-4
-
Molecular Weight 138.06
-
Formel C3H7O4P
-
SMILES
C[C@@H]1O[C@@H]1P(O)(O)=O
-
Synonyms
MK-0955
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (15)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
Antimicrobial resistance and population genomics of multidrug-resistant Escherichia coli in pig farms in mainland China. [Abstract]2022 Mar 2;13(1):1116. PMID: 35236849 -
MedComm (2020)
Novel antibiotics against Staphylococcus aureus without detectable resistance by targeting proton motive force and FtsH. [Abstract]2025 Jan 8;6(1):e70046. PMID: 39781293 -
J Exp Med
2026 Mar 2;223(3):e20241287. PMID: 41400657 -
Antibiotics (Basel)
Rapid Detection of Multiple Classes of β-Lactam Antibiotics in Blood Using an NDM-1 Biosensing Assay. [Abstract]2021 Sep 14;10(9):1110. PMID: 34572692 -
Front Cell Infect Microbiol
Fosfomycin Protects Mice From Staphylococcus aureus Pneumonia Caused by α-Hemolysin in Extracellular Vesicles by Inhibiting MAPK-Regulated NLRP3 Inflammasomes. [Abstract]2019 Jul 15:9:253. PMID: 31380296 -
Molecules
Seeking Correlation Among Porin Permeabilities and Minimum Inhibitory Concentrations Through Machine Learning: A Promising Route to the Essential Molecular Descriptors. [Abstract]2025 Mar 9;30(6):1224. PMID: 40142001 -
ACS Infect Dis
Loratadine Derivative Lo-7: A Weapon against Drug-Resistant Enterococcus and Streptococcal Infections. [Abstract]2024 Aug 9;10(8):2961-2977. PMID: 39066703 -
Microbiol Spectr
Sub-inhibitory concentrations of fosfomycin enhance Staphylococcus aureus biofilm formation by a sarA-dependent mechanism. [Abstract]2025 Sep 2;13(9):e0152125. PMID: 40689791 -
Microb Pathog
Sub-minimum inhibitory concentrations of fosfomycin enhance Staphylococcus aureus virulence through the agr-PSM pathway. [Abstract]2026 Jan:210:108138. PMID: 41429753 -
Infect Genet Evol
Polymyxin B combined with amikacin delays the resistance of Klebsiella pneumoniae to polymyxin B by modulating the expression of NlpE. [Abstract]2025 Sep:133:105780. PMID: 40480594 -
J Antibiot (Tokyo)
In vitro assessment of the synergistic effects of cefotaxime, colistin, and fosfomycin combinations against foodborne resistant Escherichia coli and Salmonella isolates. [Abstract]2025 Mar;78(4):265-273. PMID: 39910346 -
J Med Microbiol
In vitro activities of daptomycin combined with fosfomycin or rifampin on planktonic and adherent linezolid-resistant isolates of Enterococcus faecalis. [Abstract]2019 Mar;68(3):493-502. PMID: 30882300 -
Indian J Med Microbiol
Can aztreonam/avibactam combined with fosfomycin be a treatment option for infections caused by NDM-producing Pseudomonas aeruginosa?. [Abstract]2026 May 14:62:101146. PMID: 42140317 -
-
Reinheit & Dokumentation
Verweise
[1]. Falagas ME, et al. Fosfomycin. Clin Microbiol Rev. 2016 Apr. 29(2):321-47. [Content Brief]
[2]. Dijkmans AC, et al. Fosfomycin: Pharmacological, Clinical and Future Perspectives. Antibiotics (Basel). 2017 Oct 31. 6(4):24. [Content Brief]
[3]. Inouye S, et al. Mode of protective action of fosfomycin against dibekacin-induced nephrotoxicity in the dehydrated rats. J Pharmacobiodyn. 1982 Dec. 5(12):941-50. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Fosfomycin Related Classifications
HY-B1075A Related Classifications
Powered by Bioz